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Abstract
Background: In coming decades the proportion of very elderly people living in the Western world will
dramatically increase. This forthcoming “grey epidemic” will lead to an explosion of chronic diseases. In order to
anticipate booming health care expenditures and to assure that social security is funded in the future, research
focusing on the relationship between chronic diseases, frailty and disability is needed. The general aim of the
BELFRAIL cohort study (BFC80+) is to study the dynamic interaction between health, frailty and disability in a multi-
system approach focusing on cardiac dysfunction and chronic heart failure, lung function, sarcopenia, renal
insufficiency and immunosenescence.
Methods/Design: The BFC80+ is a prospective, observational, population-based cohort study of subjects aged 80
years and older in three well-circumscribed areas of Belgium. In total, 29 general practitioner (GP) centres were
asked to include patients aged 80 and older. Only three exclusion criteria were used: severe dementia, in palliative
care and medical emergency. Two sampling methods for the recruitment of patients were used. Between
November 2, 2008 and September 15, 2009, 567 subjects were included in the BFC80+ study. Every study participant
was invited to undergo four study visits. The GP recorded background variables and medical history and
performed a detailed anamnesis and clinical examination. The clinical research assistant performed an extensive
examination including performance testing, questionnaires and technical examinations. Echocardiography was
performed at home by a cardiologist. A blood sample was collected in the morning. Follow-up reporting of hard
outcome measures including mortality, hospitalization and morbidity was organized. A second data collection is
planned after 18 months.
Discussion: The BFC80+ was designed to acquire a better understanding of the epidemiology and pathophysiology
of chronic diseases in the very elderly and to study the dynamic interaction between health, frailty and disability in
a multi-system approach. The wide variety of dimensions investigated in the BFC80+ will enable us not only to
investigate in depth the relationship between the different physiological systems but also to initiate new research
questions based on this unique database of community-dwelling elderly.
Background
Health care and social security systems in industrialized
countries are confronted with ageing populations. By
2050, 10% of people living in Belgium will have reached
the age of 80 or older [1]. This forthcoming “grey epi-
demic” will lead to an explosion of chronic diseases.
This situation has stimulated researchers to focus their
efforts on studying relationships between chronic dis-
eases, frailty and the development of disability [2,3].
Fried et al. [4] have clearly shown that there is an over-
lap between chronic diseases, frailty and disability. In
this regard the concept of frailty fulfils an important
role. Although there are a large variety of models, defi-
nitions and criteria, a consensus view exists that consid-
ers frailty as a multidimensional geriatric syndrome with
biological, physiological and psychosocial components,
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adaptability to stress [5,6]. Campbell and Buchner [7]
described frailty as a condition or syndrome which
results from a multi-system reduction in reserve capa-
city to the extent that a number of physiological systems
are close to, or past, the threshold of symptomatic clini-
cal failure. A better understanding of the dynamic pro-
cess leading from health to frailty and eventually
disability is of primary interest if preventive interven-
tions are planned.
In Belgium general practitioners (GPs) have a promi-
nent place in the health care system. More than 95% of
the population is reported to consult the same GP or
practice (duo or group) in case of health problems. More
than 90% of people aged 65 and older have at least one
contact with their GP every year, with an average of 11.9
contacts per year at the age of 75 and older [8].
The general aim of the BELFRAIL cohort study is to
acquire a better understanding of the epidemiology and
pathophysiology of chronic diseases in the very elderly
and to study the dynamic interaction between health,
frailty and disability in a multi-system approach. There-
fore the BFC80+ focuses on different systems; (1) cardiac
dysfunction and chronic heart failure, (2) lung function,
(3) sarcopenia, (4) renal insufficiency and (5) immuno-
senescence and the profile of immune risk.
Cardiac dysfunction and chronic heart failure
In our ageing society the burden of chronic heart failure
is rising. The prevalence increases with age from 0.7% in
people aged 55-64 years to 2.7% in those aged 65-74
years and 13.0% in those aged 75-84 years [9]. Heart
failure not only has negative consequences for functional
status and well-being but also leads to increased mortal-
ity [9]. However, diagnosing chronic heart failure is
notoriously difficult, especially in the elderly who often
have multiple comorbidities and may present with many
other possible causes for dyspnoea, fatigue or peripheral
oedema. With increasing average patient age, primary
care physicians will become increasingly important as
the principal diagnosticians and treating physicians. In
this setting, poor availability of routine echocardiogra-
phy leads to considerable over- and under-diagnosis of
heart failure [10,11]. This emphasizes the need for a
simple test, easily applicable in primary care settings, to
identify elderly patients at risk and to initiate timely
treatment to reduce mortality and improve quality of
life. Over the last decade, brain natriuretic peptide
(BNP) and its amino-terminal portion N-terminal pro-
brain natriuretic peptide (NT-proBNP) have been exten-
sively studied. However, a recent systematic review
found limited evidence for the usefulness of natriuretic
peptide measurement for the diagnosis of cardiac dys-
function or heart failure in community-dwelling elderly
patients aged 75 and over and concluded that important
questions about the implementation of the natriuretic
peptide test in daily practice remain unsolved [12]. The
BFC80+ was conceived (1) to examine further the diag-
nostic accuracy of natriuretic peptides for cardiac dys-
function in elderly people in the community and (2) to
develop an algorithm, easily applicable in primary care,
for the diagnosis of chronic heart failure in the very
elderly by estimating the added value of natriuretic pep-
tides and ECG beyond history taking and clinical
examination.
Lung function
With regard to the burden of respiratory diseases in the
elderly, many fundamental issues remain unresolved.
Few reliable data are available concerning the prevalence
of chronic obstructive pulmonary disease (COPD) and
asthma [13], and the global initiative for chronic
obstructive lung disease (GOLD) criteria [14] for the
diagnosis of COPD have been debated and appear not
to be meaningful in the elderly [15]. Moreover, the lack
of clear reference data for the very elderly makes assess-
ment of pulmonary function a real challenge [16,17].
Predictive models for spirometric variables have been
proposed but are based on very small samples that are
rarely representative of the population in an area [18].
Two aims of the BFC80+ study are (1) to collect respira-
tory reference data from a lar g es a m p l eo ft h ee l d e r l y
population in Belgium in order to develop an adapted
predictive model (regression equation that allows com-
putation of predicted values) and (2) to gain better
insight into the prevalence of respiratory symptoms and
obstructive lung disease in octogenarians. Clustering
with other chronic diseases will also be studied, and the
ability of older patients to perform good-quality spiro-
metric tests will be investigated.
Sarcopenia
Sarcopenia has been described as an age-related decline
in muscle mass in older people [19]. Current definitions
of sarcopenia include both a loss of muscle strength and
a decline in functional quality in addition to the loss of
muscle protein mass [20]. However, it is unclear
whether a decline in functional capacity results from the
loss of muscle mass and/or the qualitative impairment
of the muscle tissue [21]. The age-associated changes in
muscle mass explain less than 5% of the variance in the
change in strength with ageing [20]. Sarcopenia is asso-
ciated with many adverse outcomes like increases in
morbidity, falls, institutionalization and onset of disabil-
ity [22]. It has been suggested that the contribution of
muscle mass to certain outcomes may be primarily
because of its association with muscle strength [20].
Decreased strength, most often grip strength, has been
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strength appears to be a robust predictor of functional
decline, disability and mortality [19]. In the BFC80+ the
relationship between grip strength, muscle mass and
clinical outcome will be studied. Also the relationship
with nutritional status, performance tests and biological
indicators will be investigated.
Renal insufficiency
Chronic kidney disease (CKD) is increasingly recognized
as an important problem in public health because of its
high prevalence [24] and its association with increasing
mortality, cardiovascular events and hospitalizations
[25]. “Gold standard tests” based on ethylenediaminete-
traacetic acid (EDTA), inulin, iohexol or diethylene tria-
mine pentaacetic acid (DTPA) clearance that aim to
measure the glomerular filtration rate (GFR) are difficult
to perform in clinical practice. Cockcroft and Gault [26]
developed a method to estimate renal function based on
the serum creatinine value and the patient’s body weight
and age. Since then, many researchers have tried to find
a better formula based on serum creatinine or cystatin
C [27]. However, none of these methods has been vali-
dated in a large population of community-dwelling
elderly patients. The aims of the BFC80+ are, first, to
achieve a better understanding of the prevalence, com-
plications and evolution of CKD in elderly patients, and
second, to identify the most accurate existing method or
to develop a new method, applicable in clinical practice,
to estimate the GFR in elderly patients.
Immunosenescence and the immune risk profile
Deterioration of the immune system with ageing,
referred to as immunosenescence, is believed to be a
prominent pathophysiological feature of frailty [28]. The
hallmarks of immunosenescence are a decrease in adap-
tive immunity and increased low-grade chronic inflam-
matory status, which has been referred to as inflamm-
ageing. The former results in a decreased ability to
effectively control infectious diseases and a generally
poor response to vaccination, while inflamm-ageing
seems to underlie most of the age-related diseases (e.g.
atherosclerosis, dementia, sarcopenia, diabetes, etc.) and
has been shown to be related to mortality of all causes
in older persons [29,30]. The chronological age at which
immunosenescence becomes clinically important is most
likely influenced by many factors, including the patho-
gen load to which individuals are exposed throughout
life. There is considerable evidence that human cytome-
galovirus (CMV) in particular plays an important role in
immune modulation later in life [31]. Understanding
how and why immune responsiveness changes in
humans as they age is essential for developing strategies
to prevent or restore dysregulated immunity and assure
healthy aging. Therefore, we will explore the complex
relationship between immunosenescence and frailty, dis-
ease and death in the BFC80+. Furthermore, we will
investigate the role of CMV and other pathogens in the
process of immunosenescence and the mechanisms
underlying it.
Methods
Study design and setting
The BFC80+ is a prospective, observational, population-
b a s e dc o h o r ts t u d yo fs u b j e c t sa g e d8 0y e a r sa n do l d e r
in three well-circumscribed areas in Belgium. The study
protocol was approved by the Biomedical Ethics
Committee of the Medical School of the Université
Catholique de Louvain (UCL) of Brussels, Belgium
(B40320084685).
Sample size calculations were based on the first focus
of this study: to determine the diagnostic accuracy of
clinical signs and symptoms for heart failure. Therefore
the sample size calculation was based on the following
premises: 1) the expected prevalence of “cardinal” symp-
toms (i.e. dyspnoea, fatigue, peripheral oedema) of CHF
in octogenarians of 30%, 2) the worst-case scenario in
which none of these criteria would have any diagnostic
value (i.e. proportion of any symptom of 0,5) and taking
into account an acceptable confidence interval of 90%,
and 3) assuming a prevalence of CHF of 15% in octo-
genarians. The sample size for the BFC80+ was estimated
on 420 subjects. Taking into account a refusal rate of
not more than 10% and a yearly mortality rate of 10% a
sample size of 550 was proposed.
General practitioners in three Belgian areas were
invited to participate in the study. In Wallony (région
de Dinant), Brussels and Flanders (Druivenstreek),
respectively, 17, 2 and 10 GP centres agreed to partici-
pate. Participating centres were invited to a training
meeting in order to standardize the recording of the
medical history, anamnesis and clinical examination.
The GP centres received study information with a
detailed study protocol and a CD-ROM with visual and
audio examples of the clinical examination and recent
guidelines on heart failure and hypertension.
The participating centres were asked to include
patients aged 80 and older in the cohort. Only three
exclusion criteria were used: (1) dementia (known mini-
mental state examination (MMSE) < 15/30), (2) in pal-
liative care and (3) medical emergency. Two sampling
methods for the recruitment of patients were used. Two
GP centres were asked to include all eligible patients.
The remaining 27 centres were asked to include a maxi-
mum of three consecutive patients during a three-week
interval. In these three weeks the GP also planned his
visit. This interval was repeated five times so every par-
ticipating centre included a maximum of 15 patients.
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day to avoid selection bias.
On November 2, 2008 the inclusion period was started
in Wallony. All participating centres in this area
recruited patients according to the second sampling
method, thus a maximum of 15 patients. On February
28, 2009 inclusion was stopped in Wallony. On March
16, 2009 the inclusion period was started in Flanders
and Brussels. One centre in Flanders and one centre in
Brussels recruited all eligible patients. The remaining
centres (Flanders (n = 9), Brussels (n = 1)) recruited
patients according to the second sampling method. On
September 15, 2009 inclusion was stopped in Flanders
and Brussels.
Visit to general practitioner
Eligible patients were first flagged by the GP and
received an information letter about the study. After
providing informed consent, patients entered the study
population. In the weeks after flagging, the GP recorded
the social situation, medical history and medication for
each patient and undertook a detailed anamnesis and
clinical examination.
The social anamnesis consisted of questions about
ethnic group, marital status, type of living (at home or
institutionalized), level of education and professional
history. The GP was asked to record important antece-
dents in the medical history of the study subjects and to
list the medical problems for which the subject was cur-
rently followed. Afterwards, a detailed recording of non-
cardiovascular and cardiovascular comorbidities took
place.
Non-cardiovascular morbidities were defined as a
positive response from the GP about the presence of
thyroid problems, anaemia, asthma, COPD, Parkinson’s
disease, arthritis, osteoarthritis, documented osteoporo-
sis, malignancies, depression and renal insufficiency. A
distinction was made between an active and cured
pathology. Active status was defined as being present
(even if well controlled by treatment) or having
occurred less than six months ago. The GP was asked
whether the subject had had a knee or hip replacement
or had undergone important surgery less than or more
than 12 months ago. Tetanus, pneumococcal and influ-
enza vaccination status was registered.
Cardiovascular morbidities were defined as a positive
response for the presence of hypertension, diabetes mel-
litus, hyperlipidaemia, history of angor pectoris or myo-
cardial infarction, known cardiomyopathy, history of
transient ischaemic attack (TIA) or cerebro-vascular
accident (CVA), peripheral arterial disease, history of
decompensated heart failure, atrial fibrillation, valvular
disease or history of oedema of the lower extremities. If
present, details were requested about the date of
diagnosis, the diagnostic pathway and nature of treat-
ment. The GP was asked to report important cardiovas-
cular intervention or surgery (percutaneous transluminal
coronary angioplasty (PTCA) or stenting, coronary, valv-
ular or arterial surgery, or the placement of cardiac
device) less than or more than 12 months ago.
Current medication was recorded by the GP.
A structured and standardized anamnesis was per-
formed and included questions about symptoms of
angina pectoris (at rest or during exercise), dyspnoea
(Medical Research Council (MRC) scale), fatigue,
orthopnoea, cough (nocturnal or diurnal), wheezing,
oedema of the lower extremities, palpitations, loss of
appetite, smoking status, alcohol intake, recent changes
in symptoms, recent weight change and alteration of
mental and psychological status.
The clinical examination consisted of a blood pres-
sure measurement in the sitting position on both arms
that was repeated after 2 min. The GP used his or her
own blood pressure meter. Heart rate (with ausculta-
tion over 30 s, × 2), heart rhythm (regular or irregular)
and breathing rate at rest (with observation over 30 s,
× 2) were measured. Heart auscultation was performed
to detect an S3, S4 or cardiac murmur (systolic or dia-
stolic). The apex beat was palpated with the patient in
a supine and lateral position, and if present the GP
was asked to describe whether it was displaced (out-
side the mid-clavicular line in supine position),
enlarged (> 2 fingers) or sustained (in left lateral posi-
tion). Lung auscultation was performed to detect crepi-
tations, wheezing and rhonchi. The carotid arteries
were auscultated to detect a murmur and the periph-
eral arteries (femoral, popliteal and dorsal and tibial
arteries) were palpated. The jugular venous pressure
(JVP) was measured in a 45° reclining position and
noted if raised (> 3 cm between the angle of Louis
(manubrio-sternal joint) and the highest level of jugu-
lar (internal or external) vein pulsation). In the same
position, the presence of hepatojugular reflux was
checked for. Hepatojugular reflux was present when
the vertical height of the JVP increased by more than
1 cm and remained elevated for as long (15-20 s) as
pressure was applied to the epigastrium. The GP was
asked to determine whether hepatomegaly or oedema
of the lower extremities was present and if he or she
had a suspicion of ascites.
Finally, the GP was asked whether, in his or her opi-
nion, the patient suffered from chronic heart failure,
and to determine his or her degree of certainty (2, 10,
25, 50, 75, 90 or 98% certain). The reason why the GP
thought chronic heart failure was or was not present
was noted and the New York Heart Association
(NYHA) class scored for those patients with a suspicion
of chronic heart failure.
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patients also determined an ankle-brachial index with
the patient in supine position with oscillometric pres-
sure measurements using a standard automated blood
pressure cuff system (SCVL-2007, Diegel Healthworks®,
Auckland, New Zealand).
Visit to clinical research assistant
After inclusion of a patient, the data manager made an
appointment for the clinical research assistant (CRA) to
visit the patient. Three CRAs were trained to perform
an extensive examination with performance testing,
questionnaires and technical examinations. The French-
speaking patients were visited by a French-speaking
CRA (n = 1) and the Dutch-speaking patients by a
Dutch-speaking CRA (n = 2). This visit lasted between
90 and 150 minutes depending on the general state of
the patient. The following tests and questionnaires were
performed by the CRA:
- Biometry: circumference of upper arm, calf and
upper leg, skin fold of upper arm, calf and upper leg,
weight, height, span width and knee height.
- Blood pressure: electronically measured (Omron
705IT®, Omron, Japan) in sitting position on both
arms and repeated after 2 min.
- Vision: asking the respondent “are you able to
recognize someone’s face at a distance of four
metres?” [32].
- Hearing: asking the respondent “are you able to
follow a conversation with one and four persons?”
both with a hearing aid if needed [32].
- Incontinence: asking the respondent whether he or
she lost urine unintentionally [33].
- Performance testing: the performance-based tests
of physical function included timed measures of
walking speed, rising from a chair, putting on and
taking off a cardigan, and maintaining balance in a
tandem stand. The performance tests have been
used in several studies and have been shown to be a
reliable and valid measure of physical functioning
[34,35]. For the walking test, respondents were asked
to walk 3 metres, turn around, and walk back the 3
metres as quickly as possible. For the chair-stand
test, respondents were asked to fold their arms
a c r o s st h e i rc h e s ta n dt os t a n du pf r o mas i t t i n g
position and sit down five times as quickly as possi-
ble. For the cardigan test, respondents were asked to
put on and take off the cardigan. For the ability to
maintain balance in tandem stand the respondent
was asked to put the heel of one foot in front of the
other and to stand still as long as possible.
Categories of performance were created for each set
of performance measures to permit analyses that
i n c l u d e dt h o s eu n a b l et op e r f o r mat a s k .F o rt h e
walking test, chair-stand test and cardigan test, those
who could not complete the task were assigned a
score of 0. Those completing the task were assigned
scores of 1 to 4, corresponding to the quartiles of
time needed to complete the task, with the fastest
time scored as 4. For the balance in tandem stand a
score of 0 was assigned to those who were unable to
perform the test or maintained the tandem stand for
less than 3 seconds (< 3 s). For those maintaining a
tandem stand for more than 3 seconds but less than
10 seconds (3-9.99 s) a score of 1 was assigned and
for those maintaining the tandem stand for 10 sec-
onds or more a score of 2. A summary performance
scale, ranging from 0 to 14, was created by summing
the category scores.
- Activities of daily living (ADL): functional limita-
tions were assessed by asking the respondent to
describe the degree of difficulty they had with six
activities of daily living (ADL): climbing stairs, walk-
ing 5 min outdoors without resting, getting up and
sitting down in a chair, dressing and undressing one-
self, using own or public transportation, and cutting
one’s own toenails [36-38]. Response categories ran-
ged from (1) “No I cannot” to (5) “Yes without diffi-
culty.” The total score was calculated by summing the
scores of all activities and ranged between 6 and 30.
- LASA Physical Activity Questionnaire (LAPAQ)
[39]: the LAPAQ is a face-to-face questionnaire
http://www.lasa-vu.nl that covers the frequency and
duration of walking outside, bicycling, gardening,
light household activities, heavy household activities,
and a maximum of two sport activities during the
previous two weeks. Walking and bicycling for trans-
portation purposes are considered as common daily
activities, and not as sport activities. The duration of
the activities assessed with the LAPAQ was categor-
ized into six groups. The duration of the activities, 0,
1-15, 16-30, 31-60, 61-120 and > 120 min per day,
were assigned scores 0, 1, 2, 3, 4 and 5 (called the
duration score), respectively. The total score of the
LAPAQ for each activity in two weeks was calcu-
lated by multiplying the frequency of the activity by
the duration score. For instance, eight walking ses-
sions of 45 min each in two weeks corresponded to
eight × duration score 3 = 24. If the activity was per-
formed several times per day, the total duration of
that activity per day was calculated. For example, 45
walking sessions of 10 min each in two weeks corre-
sponded to (45 × 10)/14 = 32 min of walking per
day. In this example the score for walking was 14 ×
duration score 3 = 42. The total activity was calcu-
lated by summing the scores of the individual activ-
ities over two weeks.
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Geriatric Depression Scale (GDS-15) is the shor-
tened, less time-consuming version of the 30-item
GDS which has been especially designed to screen
for depression in the elderly [40]. Both the long and
the short form of the GDS focus on functional and
mood symptoms of depression rather than on poten-
tially misleading somatic features. Several studies
have validated the use of the GDS-15 for screening
for depressive disorders in old age in geriatric inpati-
ents [41], outpatients [42] and in primary care [43].
It has been shown that the GDS-15 has a good accu-
racy in screening for depression in the community-
living very elderly [44].
- MMSE [45]: cognitive function was assessed by the
M M S E ,w i t hs c o r e sr a n g i n gf r o m0t o3 0p o i n t s
(optimal). The test evaluates in a global way cogni-
tive efficiency by examining orientation in time and
space, short- and middle-term memory, calculation,
comprehension and constructive praxis. Any score
greater than or equal to 25 points is effectively nor-
mal (intact). Below this, scores can indicate severe (≤
9 points), moderate (10-20 points) or mild (21-24
points) deficits [46]. The raw score may also need to
be corrected for educational attainment and age.
- Barthel Index [47]: the Barthel Index consists of 10
items that measure a person’s daily functioning, spe-
cifically the activities of daily living and mobility.
The items include feeding, moving from chair to bed
and return, grooming, transferring to and from a toi-
let, bathing, walking on a level surface, going up and
down stairs, dressing, and continence of bowels and
bladder. The assessment can be used to determine a
baseline level of functioning and can be used to
monitor improvement in activities of daily living
over time. The items are weighted according to a
scheme developed by the authors [47]. The person
receives a score based on whether they have received
help while doing the task. The scores for each of the
items are summed to create a total score, with a
maximum score of 100. The higher the score the
more “independent” the person. Independence
means that the person needs no assistance for any
part of the task.
- Tinetti test [48]: the Tinetti test comprises a series
of tests that measures subjects’ gait and balance in
order to estimate the risk of falls. Subjects were
scored 0 to 2 on the individual items, with 0 repre-
senting the most impairment and 2 representing
independence. The individual items were combined
into three measures: (1) an overall gait score (12
points), (2) an overall balance score (16 points) and
(3) a gait and balance score (28 points). Subjects
w h os c o r e d2 5t o2 8w e r ec l a s s i f i e da sa tl o wr i s ko f
falls. Those who scored 19 to 24 points were classi-
fied as at moderate risk of falls and those who
scored 18 or below were classified as at high risk of
falls.
- IADL-E Lawton: the ability of subjects to perform
instrumental activities of daily living (IADL-E) was
measured using the scale developed by Lawton and
Brody [49]. The instrument consists of eight items
(ability to use telephone, shopping, food preparation,
housekeeping, laundry, mode of transportation,
responsibility for own medications and ability to
handle finances) and has been widely accepted as a
valid and reliable measure for use in elderly commu-
nity populations. One item was added, namely the
ability to repair and maintain the house. The scale
was completed by the CRA during a home visit
using the “best available” information, which
included self-report, CRA observation, or proxy
report. Responses were recorded for each item. To
i m p r o v et h es e n s i t i v i t yo ft h es c a l e ,t h et r i a la l t e r e d
the scoring of each item from the original two-point
scale to scores which ranged from 1 to 4. Scores
increased with level of dependence, and the same
scoring system was used for both sexes. If it was
impossible to score an item, this item was excluded
from the overall score. Scores ranged from 9/36
(independent) to 36/36 (complete dependency).
- IADL (Katz-score): the Katz Index of Activities of
Daily Living is an assessment tool that is frequently
used with the geriatric population in many settings,
including patients’ h o m e s[ 5 0 ] .I ti su s e dt om e a s u r e
function and how it changes over time in older people
who have chronic illnesses. The Katz scale considers
six basic domains: bathing, dressing, toileting, ambulat-
ing or transferring, continence and feeding. For each of
the six function domains, five possible function levels
are scored ranging from complete independence (6/
30) to complete dependence (30/30).
- The Groningen Frailty Indicator (GFI): this is a
short 15-item questionnaire aiming to identify
patients that have diminished reserves in one or
more of the core domains of functioning [51,52].
These domains are: mobility, physical fitness, comor-
bidity, weight loss, vision, hearing, cognition and
psychosocial resources. It has empirically been
shown that all these domains are associated with a
variety of adverse outcomes. The current view on
the clinical measurement of frailty encompasses the
whole person’s functioning and physiology, empha-
sizing the interaction of physical and psychosocial
systems [53]. The GFI builds on the assumption that
strong interaction effects often exist between differ-
ent weaknesses of older patients, reinforcing each
other into a downward spiral of further decline.
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ence (SOC) was put forward by Aaron Antonovsky
in 1979 to explain why some people become ill
under stress and others stay healthy [54-56]. It arose
from the salutogenic approach, that is, the search for
the origins of health rather than the causes of dis-
ease. The SOC is defined as: “The extent to which
one has a pervasive, enduring though dynamic, feel-
ing of confidence that one’s environment is predict-
able and that things will work out as well as can
reasonably be expected.” In other words, it is a mix-
ture of optimism and control. It has three compo-
nents: comprehensibility, manageability and
meaningfulness. Comprehensibility is the extent to
which events are perceived as making logical sense,
that they are ordered, consistent and structured.
Manageability is the extent to which a person feels
they can cope. Meaningfulness is how much one
feels that life makes sense and challenges are worthy
of commitment. For this study the 13-item scale was
used. Every item was scored with a Likert scale ran-
ging from 1 to 7, generating a total scale range from
13-91, a high score representing a strong SOC.
Before calculating the total score, five items were
reversed according to the original codebook as pre-
sented by Antonovsky [57]. The division into a low
and high/medium group was dichotomized at the
lower tertile.
- Locus of Control (LOC): locus of control refers to
the extent to which individuals believe that they can
control events that affect them. Individuals with a
high internal locus of control believe that events
result primarily from their own behaviour and
actions. Those with a high external locus of control
believe that powerful others, fate, or chance primar-
ily determine events. The Multidimensional Health
Locus of Control (MHLC) Form A, developed by
Wallston and Wallston in 1978, was used [58]. The
MHLC, which is a six-point Likert scale, contains 18
questions classified into three subscales: Internal
HLC, Powerful-Others HLC, and Chance HLC. Each
subscale contains six questions. For each question
subjects chose one out of six answers ranging from
“strongly agree” to “strongly disagree”.
- Grip strength: grip strength was measured in the
dominant hand using a JAMAR® Plus digital hand-
held dynamometer. Three attempts at maximal
squeeze were recorded.
- Basic spirometry: this was performed using a
Spirobank spirometer (MIR, Rome, Italy). This is a
hand-held instrument for lung function tests that
has been wired into a computer. Winspiro software
(MIR) compares the measured values with
reference tables and automatically calculates the
reproducibility of the performed spirometry in
accordance with European Respiratory Society
guidelines [59]. The CRA enthusiastically demon-
strated the correct manoeuvres before the patient
attempted them. The minimum number of forced
vital capacity (FVC) manoeuvres required to meet
quality goals is three, but since older patients
require an average of five, up to eight manoeuvres
were performed when needed in order to meet the
goals. When patients appeared to be exhausted the
test was interrupted.
- Electrocardiogram (ECG): a 12-lead ECG was
recorded on a QRS Universal ECG device (QRS
Diagnostic, Plymouth, USA, http://www.qrsdiagnos-
tics.com. QRS medical devices are manufactured
under an ISO 13485 Registered Quality Management
System. The Universal ECG device is FDA approved
and CE Marked in accordance with medical device
directive (MDD) 93/42/EEC. An automated protocol
was produced by the QRS Diagnostic software based
on the “Louvain” diagnostic algorithm [60]. Each
ECG was digitally stored and analysed off-line by an
experienced cardiologist according to the Minnesota
Code Classification System for Electrocardiographic
Findings.
- Bio-electrical impedance (BIA): BIA is based on the
relationship between the volume of a conductor and
its electrical resistance. We used BIA mainly to esti-
mate skeletal muscle mass [61]. Validated formulas
appropriate for assessment of fat-free mass (FFM)
and skeletal muscle mass (SMM) in the elderly were
used as suggested by Duerenberg et al. [62]. The
BODYSTAT 1500 MDD device (Bodystat LTD,
Douglas, Isle of Man, UK) was used and dual-fre-
quency measurements were performed with patients
in a supine position. Patients wearing a pacemaker
were excluded from the procedure.
- Exhaled NO: Nitric oxide (NO) is detectable in the
exhaled air of humans. An increase in the concentra-
tion of exhaled nitric oxide (eNO) has been found in
asthmatic patients including those with mild disease
[63]. Levels of eNO parallel the inflammatory process
in the asthmatic airway [64]. Recommendations for
standardized procedures for measurements of exhaled
lower respiratory nitric oxide have been published by
the American Thoracic Society [65]. The NIOX
MINO portable device (Aerocrine, Solna, Sweden,
http://www.aerocrine.com was used. The device pro-
duces an auditory and visual feedback signal to guide
patients. Patients were encouraged to perform a 10-
second exhalation manoeuvre. When this appeared
difficult, a 6-second procedure was accepted.
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Echocardiograms were performed at home using a com-
mercially available portable system (CX50, Philips, And-
over, Massachusetts, USA) with M-mode, 2-dimensional,
and pulsed, continuous-wave and colour-flow Doppler
capabilities. Echocardiograms were performed by a cardi-
ology fellow fully trained in echocardiography. All
patients were examined in left lateral decubitus. A com-
plete examination comprising standard parasternal short
and long axis, apical and subcostal 2D views was per-
formed according to the recommendation of the Ameri-
can and European society of Echocardiography [66].
Colour, pulsed and continuous Doppler were used to
assess the presence and severity of valvular lesions. Dia-
stolic function was assessed using mitral flow velocities
obtained by pulsed Doppler or pulsed tissue Doppler at
the level of the mitral annulus. Additional apical and
parasternal views for assessment of tissue velocity (colour
tissue Doppler) and deformation (2D strain or speckle
tracking) were also recorded. Still frames for M-Mode,
continuous and pulsed Doppler and cineloops for assess-
ment of left ventricular (LV) function were digitally
stored on DVD and later transferred to a workstation. All
the measurements were performed off-line using Xcelera
software (Philips, Andover, Massachusetts, USA). LV
function was calculated by the Simpson biplane method.
Tissue velocity and deformation were analysed
using Q lab software (Philips, Andover, Massachusetts,
USA).
Laboratory tests
Several blood specimens were collected on each patient
after fasting (between 7.00 AM and 10.30 AM), and
immediately stored in a refrigerated container until arri-
val in the central laboratory (< 3 h after blood collec-
tion). Plasma (EDTA, heparin) or serum samples were
obtained after centrifugation. They were separated as
aliquots (n: 4-6, depending on the volume obtained) and
immediately stored frozen at -80°C until analysis. The
analytical process was organized to avoid several freeze-
thaw cycles. The biomarkers investigated included a
wide range of cardiac, renal, thyroïd, bone metabolism,
nutritional and inflammatory biomarkers, such as BNP
and NTpro-BNP, TSH and free T4, creatinine and
cystatin C, HDL- and LDL-cholesterol, total-cholesterol
and triglycerides, hemoglobin, calcium, 25-hydroxyvita-
min D, parthyroid hormone, phosphorus, transthyretin
(prealbumin), IGF1, osteocalcin, usCRP, CMV IgG, a
series of trace elements (including aluminium, zinc, cop-
per, selenium, manganese, nickel, etc.), Clara Cell pro-
teins (CC16) and surfactant protein D (SPD). A large
panel of inflammatory biomarkers and cytokines
(12 Cytokines Array 1) was analyzed using Biochip
arrays on the Evidence Investigator™ analyzer (Randox
Laboratories Limited, Crumlin, UK). The combination
of immobilised ligands specific to different bio-markers,
chemiluminescent immunoassays and charged coupled
device camera enables to analyze simultaneously the
12 cytokines using a limited volume of serum (100 μL).
All measurements were performed in the laboratories
of the Cliniques universitaires St Luc, Brussels, except
the CC16 and SPD assays, determined in the laboratory
of the Louvain centre for Toxicology and Applied Phar-
macology (LTAP, Université catholique de Louvain,
Medical School, Brussels) in accordance with strict qual-
ity controls programmes and proficiency testing
schemes. The UniCel® Dxl 800 Immunoassay System
(Beckman-Coulter, Brea, USA) was used to determine
t h eB N P ,P a r a t h y r o i dh o r m o n e( P T H ) ,T S H ,a n df r e e
T4 concentrations; the Dade-Dimension® Xpand (Sie-
mens, Deerfield, USA) was used to measure the NTpro-
BNP concentration (NTpBNP); the UniCel® DxC 800
Synchron (Beckman-Coulter, Brea, USA) was used to
measure creatinine, HDL- and LDL-cholestserol, Total-
cholesterol, triglycerides, calcium, phosphorus, trans-
thyretin, usCRP, and cystatin C. The Sysmex XE-2100
automated hematology analyser (Milton Keynes, UK)
was used to measure the hemoglobin concentrations.
The CMV IgG concentrations were measured on the
ARCHITECT® i4000SR (Abbott Diagn, Abbott Park, Illi-
nois, USA). The 25-OH-Vitamin D, IGF1, and osteocal-
cin were measured on the LIAISON® (Diasorin,
Saluggia, Italy). Twenty three trace metal elements were
simultaneously measured by Inductively Coupled Plasma
Mass Spectrometry (ICP-MS), on a 7500 Series ICP-MS
system (Agilent Technologies, Santa Clara, USA). CC16
and SPD were determined by ELISA using a Tecan pla-
teform (Männedorf, Switzerland) and reagents kits from
BioVendor (Brno, Czech Republic).
Table 1 displays the main characteristics of the
assays, including the biological matrix, reagents kits,
normal ranges, inter-assay imprecision (CV%), and the
limits of detection (LOD). The list of the 12 cytokines
analyzed together with their sensitivity is reported in
Table 2.
Study population
Between November 2, 2008 and September 15, 2009,
567 subjects were included in the BFC80+ (Figure 1).
Three hundred subjects were included using the first
sampling method and 267 using the second sampling
method. All study participants underwent at least one
study visit and 546 participants underwent all visits.
Table 3 shows the socio-demographic characteristics
of the study population. Women represented 63.1%
(n = 358) of the study population and had a mean age
of 85.0 ± 3.9 years. Male participants had a mean age of
84.3 ± 3.3 years. The majority of study participants lived
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Page 8 of 15at home (89.9%) and had a low level of education (69.5%
≤ lower secondary education). Of the participants living
at home 188 (36.9%) received professional help and 84
(16.5%) professional care at home.
There was a high burden of comorbidity in the popu-
lation under study. Only six participants (1.1%) were
free of any pathology. Non-cardiovascular morbidity was
reported in 459 participants (81.2%) (Table 4) and
Table 1 Main characteristics of the analytical methods used for the laboratory tests
Test (unit) Analyser/kits Matrix Reference range Reproducibility CV% LOD
BNP (pg/mL) DxI 800/Biosite Plasma EDTA 5-100 5.4-6.7 1
NT-proBNP (pg/mL) Dimension/Siemens Serum < 450 (> 75 yrs) 3.9-4.3 NR
TSH (μU/mL) DxI 800/Beckman Serum 0.2-3.5 3.72-4.96 0.003
Free T4 (ng/dL) DxI 800/Beckman Serum 0.9-1.8 4.3-8.8 0.5
Parathyroid hormone (pg/ml) DxI 800/Beckman Serum 16-81 2.8-6.4 1
Creatinine (mg/dL) DxC 800/Beckman Serum 0.6-1.4 1.7-9.5 0.05
Cystatin C (mg/L) DxC 800/Gentian Serum 0.5-1.0 2.95 - 4.38 <0.1
HDL (mg/dL) DxC 800/Beckman Plasma heparin > 60 2.1-3.4 5
Total cholesterol (mg/dL) DxC 800/Beckman Plasma heparin < 200 1.48-1.6 5
Triglycerides (mg/dL) DxC 800/Beckman Plasma heparin < 150 2.2-2.6 10
Haemoglobin (g/dL) Sysmex XE-2100 Whole blood 12-17 0.5-1.0 <1.0
Calcium (mg/dL) DxC 800/Beckman Serum 8.6-10.0 1.0-2.2 2
Phosphorus (mg/dL) DxC 800/Beckman Serum 2.4-4.7 0.6-3.0 0.5
Transthyretin (mg/dL) DxC 800/Beckman Serum 18-38 3.6-4.2 2
usCRP (mg/dL) DxC 800/Beckman Serum < 0.3 4.1-5.1 0.02
CMV IgG (A.U./L) Architect i4000/Abbott Plasma EDTA < 6 (normal) 6-15 (suspicion) 5.9-6.2 NA
25-OH-Vitamin D (ng/mL) Liaison/Diasorin Serum 30-100 5.2-8.4 < 5.0
IGF1 (ng/mL) Liaison/Diasorin Serum 70-140 (> 75 yrs) 5.8-6.1 < 15
Osteocalcin (ng/mL) Liaison/Diasorin Serum 3-7 7.4-7.6 < 1.0
Aluminium (μg/dL) ICP-MS, Agilent/NA Plasma heparin* 0.2-1.0 8.9 0.1
Copper (μg/dL) ICP-MS, Agilent/NA Plasma heparin* 70-170 1.22 3.0
Zinc (μg/dL) ICP-MS, Agilent/NA Plasma heparin* 70-120 1.39 5
Selenium (μg/dL) ICP-MS, Agilent/NA Plasma heparin* 5-15 1.18 0.5
CC16 ELISA Serum 2-20 4-9 1.0
SPD ELISA Serum 50-150 4.2-9.8 0.2
CV: coefficient of variation; LOD: limit of detection; BNP: brain natriuretic peptide; NT-proBNP: N-terminal pro-brain natriuretic peptide; NR: not reported; TSH:
thyroid stimulating hormone; HDL: high-density lipoprotein; usCRP: ultrasensitive C-reactive protein; CMV IgG: cytomegalovirus immunoglobulin G; NA: not
applicable; IGF: insulin-like growth factor; * special sampling tubes free of aluminium and other trace elements; CC16: Clara cell protein 16; SPD: surfactant
protein D.
Table 2 Panel of cytokines measured on the evidence investigator ™ analyzer (Randox) with their respective analytical
ranges, imprecision and sensitivities
Cytokine Array I panel Assay range Imprecision CV% LOQ
Interleukin-1 a (IL-1 a) (pg/mL) 0-500 5.9-10.7 0.8
Interleukin-1 b (IL-1 b) (pg/mL) 0-250 7.0-13.1 1.6
Interleukin-2 (IL-2) (pg/mL) 0-3000 7.2-10.0 4.8
Interleukin-4 (IL-4) (pg/mL) 0-900 6.4-10.0 6.6
Interleukin -6 (IL-6) (pg/mL) 0-900 8.7-15.4 1.2
Interleukin-8 (IL-8) (pg/mL) 0-3000 8.7-10.1 7.9
Interleukin-10 (IL-10) (pg/mL) 0-1000 6.1-9.4 1.8
Epidermal Growth Factor (EGF) (pg/mL) 0-900 4.0-7.4 2.9
Interferon-g (IFN- g) (pg/mL) 0-1500 9.1-13.4 3.5
Monocyte Chemotactic Protein-1 (MCP-1) (pg/mL) 0-1500 5.6-14.7 13.2
Tumour Necrosis Factor- a (TNF- a) (pg/mL) 0-1500 8.1-13.0 4.4
Vascular Endothelial Growth Factor (VEGF) (pg/mL) 0-3000 6.0-13.4 14.6
CV: coefficient of variation; LOQ: limit of quantification as the lowest concentration with imprecision < 20% for 20 replicates
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(Table 5). Figure 2 shows that a high proportion of the
study population had three or more non-cardiovascular
(26.4%) or cardiovascular (53.5%) pathologies.
Table 6 shows the time between the different study
visits.
Table 7 describes the basic functional status of partici-
pants in the BFC80+. In general, there was a low preva-
lence of functional limitations in the population under
study, with 9.8% having a score ≤ 15 on the ADL scale
and 10% having a score > 10 on the IADL scale. A large
number of subjects had a high score on the GDS-15
questionnaire, with 20.6% scoring ≥ 5. Only 15 subjects
(2.9%) had an MMSE score ≤ 15. In 8.7% of the study
participants, an increased risk of falls according to the
Tinetti test was found.
Follow-up
In October 2009 a basic report for every included
patient was sent back to inform the GP. This report
included the measurements of height and weight,
blood pressure measurements, the results of the per-
formance tests, ADL, MMSE, GDS-15, Barthel’sI n d e x
and Tinetti test, the unvalidated electronically gener-
ated results of the spirometry and ECG and a basic
report on major cardiac abnormalities found with
echocardiography.
A f t e raf o l l o w - u pp e r i o do fam a x i m u m1 6m o n t h s
(March 2010 for Wallony and July 2010 for Flanders
and Brussels), and yearly thereafter, a detailed follow-up
questionnaire will be sent to the participating GP cen-
tres. The GPs will be asked to fill out a questionnaire
for every included patient describing his/her health sta-
tus. The questionnaire includes questions on mortality
and cause of mortality, episodes (> 1 day) and cause of
hospitalization, change of living and family situation and
new comorbidities (fall, cardiovascular event, heart fail-
ure, new diagnosis of cancer, renal replacement therapy)
that occurred in the past 16 months. The GPs will be
asked to report changes in treatment and to record if
they changed the management of the patient based on
the basic report that was sent back. For every included
patient, the GP will be asked if he agrees that the
patient can be contacted for the follow-up examination.
In May 2010 (Wallony) and September 2010 (Flanders
and Brussels) every participant will be contacted again
for the follow-up examination. The follow-up examina-
tion will include anthropometric measurements, evalua-
tion of blood pressure, vision, hearing, incontinence,
anamnesis, performance testing, ADL, GDS-15, MMSE,
Tinetti Test, GFI, LOC, grip strength, spirometry, ECG,
bio-electrical impedance, exhaled NO, echocardiography
and new blood tests.
Figure 1 Inclusion of study participants.
Table 3 Socio-demographic data of participants in the
BELFRAIL cohort (n = 567)
n (%) Belgian population, %
Male 209 (36.9) 33.5
Age
Women 80-84 204 (36.0) 36.8
Women 85-89 116 (20.5) 20.6
Women ≥ 90 38 (6.7) 9.2
Men 80-84 130 (22.9) 21.5
Men 85-89 66 (11.6) 9.4
Men ≥ 90 13 (2.3) 2.7
Current Family Situation
Married 239 (42.5)
Divorced 11 (2.0)
Widow(er) 281 (49.9)
Single 20 (3.6)
Other 12 (2.1)
Institutionalized 57 (10.1)
Level of Education
Without qualifications 5 (0.9)
Primary school 207 (36.8)
Lower secondary education 179 (31.8)
Higher secondary education 98 (17.4)
College 55 (9.8)
University 17 (3.0)
Professional help at home 188 (36.9)
Care at home 84 (16.5)
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Data entry of all questionnaires and examination forms
is done by the data manager. Data is inserted with File-
Maker® Pro 8.0 (FileMaker Inc., Santa Clara, CA, USA)
or Microsoft Excel®. The quality of data entry is system-
atically verified by a trained researcher in order to detect
errors. SPSS 16.0 (SPSS Inc., Chicago, IL, USA) will be
used for data analysis. Analyses will combine cross-sec-
tional and prospective approaches. The prospective ana-
lyses will be performed on thee n t i r ec o h o r t .O u t c o m e
measures will be registered for every patient that under-
went at least one module of the assessment. The variety
of dimensions included in the BFC80+ will enable us to
correct for a wide range of factors in the analyses and
multivariate models.
For the cross-sectional part of the study, very few data
are missing. For most variables, less than 5% of data are
missing. Only the following variables have more missing
data: calf skin fold (n = 55, 9.7%), sense of coherence
(n = 70, 12.3%), locus of control (n = 71, 12.5%), bio-
electrical impedance (n = 278, 49.0%) and exhaled NO
(n = 311, 54.9%).
Future analysis and publications from this cohort will
be carried out using the STROBE criteria [67].
Discussion
In the BELFRAIL Cohort Study we were able to include
567 participants who underwent a thorough multi-
dimension investigation in order to take a detailed
“medical photograph” of every included subject. We
Table 4 Non-cardiovascular morbidity of participants in the BELFRAIL cohort (n = 567)
Active pathology* n (%) Cured pathology n (%) Unknown
$, n (%)
Thyroid dysfunction 51 (9.0) 23 (4.1) 1 (0.2)
Hypofunction 47 (8.4) 5 (0.9) 2 (0.4)
Hyperfunction 1 (0.2) 15 (2.7) 3 (0.5)
Anaemia 50 (8.9) 23 (4.1) 0 (0)
Asthma 27 (4.8) 7 (1.2) 5 (0.9)
COPD 65 (11.5) - 12 (2.1)
Parkinson’s disease 16 (2.8) - 3 (0.5)
Arthritis 28 (5.0) 23 (4.1) 1 (0.2)
Osteoarthritis 324 (58.0) - 4 (0.7)
Osteoporosis 125 (22.5) - 17 (3.1)
Cancer 43 (7.6) 73 (12.9) 5 (0.9)
Depression 74 (13.1) 32 (5.7) 8 (1.4)
Renal insufficiency 64 (11.4) 5 (0.9) 9 (1.6)
Hip prosthesis
£ 73 (13.0) - -
Knee prosthesis
£ 44 (7.8) - -
*Present (even if well controlled by treatment) or having occurred less than six months ago;
$Unknown or doubt by general practitioner;
£Less or more than
12 months ago.
Table 5 Cardiovascular morbidity in participants in the BELFRAIL cohort (n = 567)
n (%) Objectified*, n (%) Unknown
$, n (%)
Hypertension 396 (70.1) - 2 (0.4)
Hyperlipidaemia 245 (44.0) - 3 (0.5)
Diabetes 107 (18.9) - 4 (0.7)
Angina pectoris 93 (16.5) 58 (62.4) 24 (4.3)
Myocardial infarction 62 (11.0) 59 (95.2) 6 (1.1)
Cardiomyopathy 56 (10.0) - -
TIA 58 (10.5) 34 (58.6) 9 (1.6)
CVA 46 (8.3) 40 (87.0) 5 (0.9)
Peripheral arterial disease 52 (9.2) 43 (82.7) 15 (2.7)
Episode of decompensated heart failure 60 (10.6) 47 (78.3) 7 (1.2)
Episode of atrial fibrillation 113 (20.1) - 5 (0.9)
Chronic atrial fibrillation 58 (10.3) - -
Valvular disease 140 (24.9) 135 (96.4) 7 (1.2)
Peripheral oedema 237 (43.8) - 5 (0.9)
*The general practitioner was asked to report if the pathology was objectified at the time of the diagnosis;
$Unknown or doubt by general practitioner.
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and age of the very elderly living in Belgium. The mean
age of women and men older than 80 living in Belgium
(84.9 years and 83.9 years, respectively) [68] was com-
parable to the mean age found in this cohort. Moreover,
the fact that participants were included by their GP
enabled us to create a heterogeneous population repre-
s e n t a t i v eo ft h ev e r ye l d e r l ys i n c em o r et h a n9 0 %o f
people aged 80+ in Belgium regularly see their GP.
This is the first cohort study of very elderly people living
in Belgium. To our knowledge this is also the first cohort
of elderly in which a large set of technical examinations
(ECG, spirometry, echocardiography, bio-electrical impe-
dance, etc.) was done at home or in a nursing home. Peo-
ple aged 80+ are the fastest growing segment of the
population in industrialized countries, and their number
will peak in 2050. Research trying to understand the com-
plexity of the geriatric patient is needed in order to antici-
pate booming health care expenditures and guarantee
future fundable social security. Therefore, the BFC80+ was
designed to acquire a better understanding of the
epidemiology and pathophysiology of chronic diseases in
the very elderly, and to study the dynamic interaction
between health, frailty and disability in a multi-system
approach.
The BFC80+ focuses on cardiac dysfunction and
chronic heart failure, lung function, sarcopenia, renal
insufficiency and immunosenescence. This wide variety
of dimensions will enable us not only to investigate in
depth the relation between these different systems but
also to instigate new research questions with this unique
database of community-dwelling elderly.
List of abbreviations used
GP: general practitioner; CRA: clinical research assis-
tant; BNP: brain natriuretic peptide; NT-proBNP:
Figure 2 Number of comorbidities.
Table 6 Time in days between different study visits
Median [IQR]
GP-CRA 21 [10-37]
GP-blood test 28 [14-43]
GP-echocardiography 29 [14-43]
CRA-echocardiography 7 [3-15]
CRA-blood test 7 [4-16]
Blood test-echocardiography 3 [1-13]
IQR: interquartile range
Table 7 Functional status of the BFC80+ population (n =
567)
N Median [IQR] Cut-off value n (%)
ADL 559 25 [21-27]
GDS-15 557 2 [1-4] ≥ 5 115 (20.6)
MMSE 557 28 [25-29] ≥ 25 443 (79.5)
21-24 70 (12.6)
10-20 39 (7.0)
≤ 9 5 (0.9)
Tinetti 549 27 [24-28] 25-28 406 (74.0)
19-24 95 (17.3)
≤ 18 48 (8.7)
IADL 559 6 [6-8]
ADL: Activities of Daily Living; GDS-15: 15-item Geriatric Depression Scale;
MMSE: Mini-Mental State Examination; IADL: Instrumental Activities of Daily
Living; IQR: interquartile range.
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Page 12 of 15N-terminal pro-brain natriuretic peptide; ECG: electro-
cardiogram; COPD: chronic obstructive pulmonary dis-
ease; CKD: chronic kidney disease; GFR: glomerular
f i l t r a t i o nr a t e ;C M V :c y t o m e g a l o v i r u s ;U C L :U n i v e r s i t é
Catholique de Louvain; CD: compact disc; MMSE:
Mini-mental state examination; TIA: transient ischaemic
attack; CVA: cerebro-vascular accident; PTCA: percuta-
neous transluminal coronary angioplasty; MRC: Medical
Research Council; JVP: jugular venous pressure; NYHA:
New York Heart Association; ADL: activities of daily
living; LAPAQ: LASA physical activity questionnaire;
GDS: geriatric depression scale; IADL-E: instrumental
activities of daily living; IADL: index of activities of
daily living; GFI: Groningen frailty indicator; SOC: sense
of coherence; LOC: locus of control; MHLC: multidi-
mensional health locus of control; FVC: forced vital
capacity; ISO: International Organization for Standardi-
zation; FDA: Food and Drug Administration; BIA: bioe-
lectrical impedance analysis; FFM: fat-free mass; SMM:
skeletal muscle mass; eNO: exhaled nitric oxide; 2D:
two-dimensional; LV: left ventricular; TSH: thyroid sti-
mulating hormone; HDL: high-density lipoprotein; LDL:
low-density lipoprotein; usCRP: ultrasensitive C-reactive
protein; CMV IgG: cytomegalovirus-specific immuno-
globulin G; IGF: insulin-like growth factor; CC16: Clara
cell protein 16; SPD: surfactant protein D; CV: coeffi-
cient of variation; LOD: limit of detection; STROBE:
Strengthening The Reporting of OBservational studies
in Epidemiology.
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